EU Regulator Advises Extra Birth Control Precautions for Patients of Lilly's Mounjaro

Dow Jones11-13
 

European drug regulators advised women who take birth control pills and Eli Lilly's Mounjaro to take extra steps to ensure their contraception remains effective while on the diabetes and weight-loss drug.

The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, said it now advises patients on birth control pills to add a backup method of contraception for four weeks after starting Mounjaro, and for four weeks after each dose increase.

The CHMP said it alternatively advises Mounjaro patients to switch to a non-oral method of contraception.

The CHMP said its guidance would be disseminated to healthcare professionals by Eli Lilly following a decision by the European Commission.

Women who can become pregnant and are using Mounjaro are recommended to use contraception.

The CHMP--which is responsible for assessing the quality, safety and efficacy of medicines in the EU, and issuing recommendations to the European Commission--said there is limited information available on the effect of tirzepatide on the efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes mellitus.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment